|
|
Bristol myers Squibb Company (BMY) |
|
|
|
| |
BMY's Revenue Growth by Quarter and Year
Bristol Myers Squibb's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| BMY Revenue (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
| IV Quarter |
December |
-
|
11,985.00
|
11,068.00
|
7,945.00
|
| III Quarter |
September |
-
|
11,624.00
|
10,540.00
|
6,007.00
|
| II Quarter |
June |
-
|
11,703.00
|
10,129.00
|
6,273.00
|
| I Quarter |
March |
11,648.00
|
11,073.00
|
10,781.00
|
5,920.00
|
| FY |
|
11,648.00
|
46,385.00
|
42,518.00
|
26,145.00
|
| BMY Revenue first quarter 2022 Y/Y Growth Comment |
Bristol myers Squibb Company achieved in the first quarter 2022, above Company average Revenue improvement of 5.19% year on year, to $ 11,648.00 millions.
Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Revenue growth. While Bristol Myers Squibb Company' s Revenue increase of 5.19% ranks overall at the positon no. 419 in the first quarter 2022.
|
| BMY Revenue ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
8.29 % |
39.31 % |
33.02 % |
| III Quarter |
September |
- |
10.28 % |
75.46 % |
5.55 % |
| II Quarter |
June |
- |
15.54 % |
61.47 % |
9.98 % |
| I Quarter |
March |
5.19 % |
2.71 % |
82.11 % |
14 % |
| FY |
|
- |
9.09 % |
62.62 % |
15.89 % |
BMY Revenue (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
3.11 % |
5.01 % |
32.26 % |
| III Quarter |
September |
- |
-0.68 % |
4.06 % |
-4.24 % |
| II Quarter |
June |
- |
5.69 % |
-6.05 % |
5.96 % |
| I Quarter |
March |
-2.81 % |
0.05 % |
35.7 % |
-0.89 % |
| FY (Year on Year) |
|
- |
9.09 % |
62.62 % |
15.89 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 18.59 % |
1.29 % |
-8.06 % |
| (Mar 31 2020) |
|
(March 31, 2013) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 18.59 % |
1.29 % |
-8.06 % |
| (Mar 31 2020) |
|
(March 31, 2013) |
|
| Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Bristol Myers Squibb's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 35.7 % |
1.49 % |
-15.91 % |
| (Mar 31 2020) |
|
|
| BMY's I. Quarter Q/Q Revenue Comment |
In the I. Quarter 2022 Bristol Myers Squibb Company reported fall in Revenue from the forth quarter by -2.81% to $ 11,648.00 millions, from $ 11,985.00 millions released in the previous quarter.
Although seasonal factors normally energize I. Quarter 2022 Revenue, it plainly has not been sufficient to salvage BMY's performance, Rodrigo Marques, market advisor from Lisbon pointed out.
Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Bristol Myers Squibb's Revenue growth quarter on quarter, overall rank is 384. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 35.7 % |
1.49 % |
-15.91 % |
| (Mar 31 2020) |
|
|
| BMY's I. Quarter Q/Q Revenue Comment |
In the I. Quarter 2022 Bristol Myers Squibb Company reported fall in Revenue from the previous quarter by -2.81% to $ 11,648.00 millions, from $ 11,985.00 millions released in the previous quarter.
Even cyclical factors which commonly energize I. Quarter 2022 results, it plainly was not sufficient to rescue Bristol Myers Squibb's I. Quarter performance, Rodrigo Marques, market advisor from Lisbon said.
Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Bristol Myers Squibb's Revenue growth quarter on quarter, overall rank is 384. |
|
Bristol Myers Squibb's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Mar 31 2022) |
12 Months Ending
(Dec 31 2021) |
12 Months Ending
(Sep 30 2021) |
12 Months Ending
(Jun 30 2021) |
12 Months Ending
(Mar 31 2021) |
| Cumulative Revenue 12 Months Ending |
$ 46,960.00 |
$ 46,385.00 |
$ 45,468.00 |
$ 44,384.00 |
$ 42,810.00 |
| Y / Y Revenue Growth (TTM) |
9.69 % |
9.09 % |
15.42 % |
27.31 % |
38.07 % |
| Year on Year Revenue Growth Overall
Ranking |
# 2285 |
# 335 |
# 1703 |
# 74 |
# 45 |
| Seqeuential Revenue Change (TTM) |
1.24 % |
2.02 % |
2.44 % |
3.68 % |
0.69 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 2305 |
# 665 |
# 2335 |
# 241 |
# 2407 |
| Cumulative Revenue growth
Comment |
Bristol Myers Squibb saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.69% year on year, to $ 46,960 millions if the fiscal year would have ended in Mar 31 2022.
Bristol Myers Squibb's trailing twelve months Revenue growth was higher than company's average 6.3% and higher than 9.09% growth in Dec 31 2021.
But from the previous reporting period increase was less at 1.24 % from $46385 millions achieved in the period from Dec 31 2021 to Mar 31 2021 Rodrigo Marques went on.
There is drop-off happening, more evident if you pay attention to the usual Q/Q TTM Revenue increase what is better at1.29%.
The progress was much stronger sequentially showed at 1.24 % rise from $46385 millions in the period from Dec 31 2021 to Mar 31 2021.
In the Healthcare sector 321 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 335 to 2285. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
18.59 % |
1.29 % |
-8.06 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
62.97 % |
6.3 % |
-24.59 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 112 |
| Sector |
# 349 |
| S&P 500 |
# 2305 |
|
| Cumulative Revenue growth
Comment |
Bristol Myers Squibb saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.69% year on year, to $ 46,960 millions if the fiscal year would have ended in Mar 31 2022.
Bristol Myers Squibb's trailing twelve months Revenue growth was higher than company's average 6.3% and higher than 9.09% growth in Dec 31 2021.
But sequential increase was slower at 1.24 % from $46385 millions reported in twelve months ending a quarter Dec 31 2021.
We witness drop-off developing, more obvious if you pay attention to the typical sequential Revenue rise that is higher at 1.29%.
The momentum is even stronger sequentially clinched at 1.24 % jump from $46385 millions in twelve months ending a quarter before.
In the Healthcare sector 321 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 335 to 2285. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
18.59 % |
1.29 % |
-8.06 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
62.97 % |
6.3 % |
-24.59 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 112 |
| Sector |
# 349 |
| S&P 500 |
# 2305 |
|
8.89%